The only FDA-approved CXCR4 antagonist, AMD3100, sensitizes ovarian cancer to chemotherapy [14] and impairs the epithelial–mesenchymal transition (EMT) when coupled with paclitaxel (PTX)-loaded bovine serum albumin (BSA) nanoparticles [15,16]. Here, CXCR4 is linked to ovarian carcinoma.